NEXT-MS
Personalized extended interval dosing of natalizumab in relapsing remitting multiple sclerosis
What was tested
Treatment tested
- Natalizumab
Integrin alpha-4/beta-1 inhibitor|Integrin alpha-4/beta-7 inhibitor
What it measured
Main measures
Radiological disease activity (new/enlarging T2 lesions on brain MRI)
MRI lesions
Other measures (1)
1) Percentage of patients preferring personalized treatment over standard treatment and percentage staying on personalized treatment
Loading reviews and guidelines…
Related trials
- Pregnancy Exposure Registry for Vumerity (Diroximel Fumar…
Recruiting
Still running
- A Study Utilising Data From European Union (EU) National …
Running, not recruiting
Still running
- SATURATE-MS
Stopped early
Stopped early
- A Study to Investigate the Radiological Onset of Action A…
Phase 4 · Stopped early
Stopped early
- The 'Wearing Off' Effect of DMT
Completed
No result found
- A Study to Evaluate Efficacy, Safety, Pharmacokinetics, a…
Phase 3 · Stopped early
Stopped: not working
History
- In scope changed from true to false
Started
Oct 2019
Assembled by software from public sources and not checked by people. Each record links to its source. Report an error